Desensitization in kidney transplantation: Review and future perspectives

Clinical Transplantation

Volumn 28, Issue 4, 2014, Pages 494-507

  Abu Jawdeh, Bassam G ^a   Cuffy, Madison C ^a   Alloway, Rita R ^a   Shields, Adele Rike ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Alloantibodies; Allosensitization; Antibody mediated rejection; Bortezomib; Immunoadsorption; Intravenous immunoglobulins; Plasmapheresis; Proteasome inhibitor; Rituximab

Indexed keywords

ALBUMIN; ALEMTUZUMAB; ALLOANTIBODY; ANTIMETABOLITE; AZATHIOPRINE; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; FRESH FROZEN PLASMA; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; TACROLIMUS; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ANTIGEN ANTIBODY COMPLEX; CELL MATURATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DESENSITIZATION; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG HEMORRHAGE; LYMPHOCYTE PROLIFERATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENECTOMY; THERAPY EFFECT; BLOOD; GRAFT REJECTION; IMMUNOLOGY; PREOPERATIVE CARE; PROCEDURES; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84899050199     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12335     Document Type: Review

References (71)

1. United States Renal Data System. Accessed at http://www.usrds.org/.
2. Evans RW, Manninen DL, Garrison LP Jr. et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985: 312: 553.
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation-a prospective study. Transplantation 1992: 54: 656.
4. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993: 270: 1339.
5. Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002: 13: 1358.
6. Cosio FG, Alamir A, Yim S et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998: 53: 767.
7. United Network For Organ Sharing Home Page. Accessed at http://www.unos.org.
8. Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011: 365: 318.
9. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011: 6: 922.
10. Jones JV, Cumming RH, Bucknall RC, Asplin CM. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976: 1: 709.
11. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976: 1: 711.
12. Ferrara GB, Tosi RM, Azzolina G, Carminati G, Longo A. HL-A unresponsiveness induced by weekly transfusions of small aliquots of whole blood. Transplantation 1974: 17: 194.
13. Taube DH, Williams DG, Cameron JS et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984: 1: 824.
14. Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher 2010: 25: 240.
15. Morath C, Beimler J, Opelz G et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012: 25: 506.
16. Van Loghem E, Frangione B, Recht B, Franklin EC. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol 1982: 15: 275.
17. Glotz D, Antoine C, Julia P et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004: 17: 1.
18. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006: 6: 859.
19. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004: 77: 542.
20. Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011: 68: 1156.
21. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004: 8: 535.
22. Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000: 70: 1531.
23. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003: 3: 1017.
24. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008: 86: 96.
25. Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009: 87: 268.
26. Haririan A, Nogueira J, Kukuruga D et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009: 9: 536.
27. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989: 1: 10.
28. Bartel G, Wahrmann M, Regele H et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010: 10: 2033.
29. Higgins RM, Bevan DJ, Carey BS et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996: 348: 1208.
30. Lorenz M, Regele H, Schillinger M et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005: 79: 696.
31. Glotz D, Haymann JP, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993: 56: 335.
32. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758.
33. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553.
34. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631.
35. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008: 359: 242.
36. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010: 89: 1095.
37. Nair V, Sawinski D, Akalin E et al. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant 2012: 26: E261.
38. Alachkar N, Lonze BE, Zachary AA et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012: 94: 165.
39. Marfo K, Ling M, Bao Y et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012: 94: 345.
40. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256.
41. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006: 6: 346.
42. Vo A, Choi J, Lukovsky M et al. Interim analysis of a double-blinded placebo controlled trial of IVIG v. IVIG + rituximab for desensitization of highly-HLA sensitized (PRA>80%) (HS) deceased donor (DD) candidates. Am J Transplant 2013: 13(Suppl 5): 76 abstract #153.
43. Bachler K, Amico P, Honger G et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010: 10: 1254.
44. Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005: 79: 742.
45. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005: 66: 359.
46. Anglicheau D, Loupy A, Suberbielle C et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study. Am J Transplant 2007: 7: 1185.
47. Lefaucheur C, Nochy D, Hill GS et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007: 7: 832.
48. Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009: 87: 227.
49. Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003: 76: 1444.
50. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003: 29(Suppl 1): 3.
51. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008: 359: 906.
52. Anderson KC. The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012: 30: 445.
53. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006: 11: 5.
54. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008: 86: 1754.
55. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010: 89: 277.
56. Guthoff M, Schmid-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012: 26: 171.
57. Wahrmann M, Haidinger M, Kormoczi GF et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010: 89: 1385.
58. Diwan TS, Raghavaiah S, Burns JM, Kremers WK, Gloor JM, Stegall MD. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011: 91: 536.
59. Kute VB, Vanikar AV, Trivedi HL et al. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience. Saudi J Kidney Dis Transpl 2011: 22: 662.
60. Woodle ES, Sadaka B, Walsh RC et al. Prospective, iterative, phased, trial of proteasome inhibitor-based desensitization in highly sensitized renal transplant candidates. Am J Transplant 2013: 13(Suppl 5): 76 abstract #151.
61. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005: 293: 1883.
62. Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005: 5: 1914.
63. Al-Jedai A, Alsultan M, Almeshari K et al. Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis. Ann Transplant 2012: 17: 82.
64. Walsh RC, Brailey P, Girnita A et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011: 91: 1218.
65. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887.
66. Sonnenday CJ, Ratner LE, Zachary AA et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002: 34: 1614.
67. Rogers NM, Eng HS, Yu R et al. Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks. Transpl Int 2011: 24: 21.
68. Hiesse C, Kriaa F, Rousseau P et al. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant 1992: 7: 944.
69. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006: 6: 2384.
70. Vo AA, Petrozzino J, Yeung K et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013: 95: 852.
71. Guthoff M, Schmid-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012: 26: 171.